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Abstract
Case reports describe significant norovirus gastroenteritis morbidity in immunocompromised 
patients. We evaluated norovirus pathogenesis in prospectively enrolled solid organ (SOT) and 
hematopoietic stem cell transplant (HSCT) patients with diarrhea who presented to Texas 
Children’s Hospital and submitted stool for enteric testing. Noroviruses were detected by real-time 
reverse transcription polymerase chain reaction. Clinical outcomes of norovirus diarrhea and non-
norovirus diarrhea patients, matched by transplanted organ type, were compared. Norovirus 
infection was identified in 25 (22%) of 116 patients, more frequently than other enteropathogens. 
Fifty percent of norovirus patients experienced diarrhea lasting ≥14 days, with median duration of 
12.5 days (range 1 – 324 days); 29% developed diarrhea recurrence. Fifty-five percent of 
norovirus patients were hospitalized for diarrhea, with 27% requiring intensive care unit (ICU) 
admission. One HSCT recipient developed pneumatosis intestinalis. Three HSCT patients expired 
≤6 months of norovirus diarrhea onset. Compared to non-norovirus diarrhea patients, norovirus 
patients experienced significantly more frequent ICU admission (27% vs. 0%, p = 0.02), greater 
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serum creatinine rise (median 0.3 vs. 0.2 mg/dL, p = 0.01), and more weight loss (median 1.6 vs. 
0.6 kg, p < 0.01). Noroviruses are an important cause of diarrhea in pediatric transplant patients 
and are associated with significant clinical complications.
Keywords
norovirus; diarrhea; transplant; children; solid organ transplantation; hematopoietic stem cell 
transplantation
Introduction
Noroviruses (NoVs) are the most common cause of foodborne disease and acute non-
bacterial gastroenteritis in the US and worldwide. In the US, approximately 19–21 million 
cases of NoV infection occur each year (1). NoV gastroenteritis contributes to ~70,000 
hospitalizations (1) and is the second most common cause of US gastroenteritis-related 
mortality, leading to ~800 deaths annually, particularly among the elderly and infants (2). 
With the success of the rotavirus vaccine, NoVs have emerged as the leading cause of US 
healthcare visits for acute gastroenteritis in immunocompetent children (3). Genogroup I 
(GI) and II (GII) NoVs are the most common NoV genetic groups causing gastroenteritis in 
humans. The GII.4 genotype predominates worldwide (4); however, geographic and 
temporal variation in NoV genotype frequency may be observed (5).
Diarrhea is commonly experienced among both solid organ (SOT) and hematopoietic stem 
cell transplant (HSCT) patients, occurring in up to 90% of transplant patients (6–9). 
Mortality rates of up to 55% have been associated with infectious diarrhea in these 
immunocompromised patients (10). Up to 60% of diarrheal episodes in transplant recipients 
have no specific etiology identified (10, 11).
NoVs represent a potentially important, underestimated enteric pathogen in the 
immunocompromised transplant population. Lack of clinical suspicion of NoVs as a cause 
of diarrhea and of available, sensitive molecular diagnostics at healthcare institutions has 
likely led to a significant underestimation of NoV epidemiology, particularly among 
immunocompromised patients. However, increasing NoV case reports among SOT and 
HSCT patients suggest that NoV infection may cause significant morbidity in these patient 
populations (12–15). These studies highlight the need to examine NoV infection as a cause 
of diarrhea in immunocompromised patients. We conducted a prospectively enrolled, 
epidemiologic surveillance study to evaluate the prevalence and clinical significance of 
norovirus diarrhea among pediatric transplant recipients at Texas Children’s Hospital (TCH) 
in Houston, Texas. TCH is one of the largest US children’s hospitals and has one of the most 
active pediatric SOT and HSCT programs worldwide, performing approximately 100 SOTs 
and over 100 HSCTs each year. We have previously demonstrated that NoVs are the most 
commonly recognized enteric pathogen in the TCH general pediatric population (16).
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Materials and Methods
Study Population
Pediatric SOT and HSCT recipients with diarrhea, presenting as outpatients or admitted to 
TCH and who submitted a stool specimen to the TCH microbiology laboratory for 
enteropathogen testing, were screened for enrollment. Subjects who met the definition of 
diarrhea were prospectively enrolled. Clinical information was collected by reviewing 
medical records. The Baylor College of Medicine Institutional Review Board approved the 
study protocol (protocol number: H-31513).
Definitions
Diarrhea was defined as a change in bowel habits with passage of ≥3 unformed stools within 
a 24-hour period or medical documentation of diarrhea by the treating healthcare provider. 
Diarrhea resolution was considered as a ≥48 hour period during which no unformed stools 
were passed (17). Diarrhea recurrence was defined as a recurrent diarrhea episode occurring 
>1 week after but ≤4 weeks of diarrhea resolution. Subjects who experienced diarrhea 
resolution, but developed a diarrhea relapse ≤1 week afterwards were considered to have 
continuation of their original diarrhea episode. Persistent diarrhea was defined as diarrhea 
duration ≥14 days (18). Diarrhea with onset in the community or ≤48 hours after hospital 
admission was described as community-associated diarrhea. Onset of diarrhea >48 hours 
after hospital admission was considered as healthcare-associated diarrhea (19).
Norovirus detection
Stool specimens from all subjects were tested for noroviruses upon enrollment. Subsequent 
stools collected at the discretion of the patient’s healthcare provider and received ≥14 days 
after a previously collected stool were also tested. Viral RNA was extracted from a 10% 
stool suspension in 0.01 M PBS using the QIAamp Viral RNA kit (QIAGEN) according to 
the manufacturer’s directions. GI and GII NoV-positive and NoV-negative control stools 
were included in each RNA extraction experiment. RNA extracts were kept at −80°C prior 
to use.
Viral RNA extracts were amplified in a duplex, real-time (TaqMan®) reverse transcription 
polymerase chain reaction (RT-PCR), using the AgPath-ID™ One-Step RT-PCR Kit 
(Applied Biosystems). Each 25 µL real-time RT-PCR reaction mixture consisted of 3 µL of 
RNA template, 400 nM of each primer (COG1F and COG1R for GI NoVs, COG2F and 
COG2R for GII NoVs), and 200 nM of probe (RING1c and RING2 for GI and GII NoVs, 
respectively; Table 1) (20). Real-time RT-PCR amplification was performed with a StepOne 
ABI Real Time PCR system (Applied Biosystems): cDNA synthesis at 45°C for 10 min, 
DNA denaturation at 95°C for 10 min, followed by 45 cycles of 95°C for 15 sec to melt 
DNA and 60°C for 60 sec to anneal and extend primers. In each run, GI.1 Norwalk and GII.
4 HOV 2009 RNA transcripts were used as controls and to generate GI and GII-specific 
standard curves by 10-fold serial dilutions (106 to 102 genome copies) of purified NoV GI 
and GII RNA transcripts, respectively. GI.1 Norwalk and GII.4 HOV 2009 RNA transcripts 
were in vitro transcribed by using pCR2.1 TOPO plasmid (Invitrogen) and pGEM-11z 
plasmid (Promega Corporation), respectively. RNA transcripts were aliquoted into 0.5 ml 
Ye et al. Page 3
Am J Transplant. Author manuscript; available in PMC 2016 July 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
tubes and stored at −80°C prior to use. The detection limit for the real-time RT-PCR assay is 
100 GI or GII NoV genomic copies, which has been established by testing 10-fold serial 
dilutions of the transcribed RNAs.
Norovirus Genotyping
NoV genotypes were identified through sequence analysis of PCR amplicons from all NoV-
positive stools. Conventional RT-PCR was performed to sequence real-time RT-PCR-
positive specimens. Briefly, 3 µL of viral RNA was amplified using 400 nM of each 
oligonucleotide primer (G1SKF, G1SKR and G2SKF, G2SKR for GI and GII NoVs, 
respectively) and the AgPath-ID™ One-Step RT-PCR Kit (Applied Biosystems) in a final 
25 µL reaction volume. After 10 min of reverse transcription at 45°C, followed by heat 
activation of Taq polymerase for 10 min at 95°C, PCR was carried out using 40 cycles at 
94°C for 30 sec, 50°C for 30 sec, and 72°C for 60 sec followed by final extension for 5 min 
at 72°C. RT-PCR products of the expected size were extracted after gel electrophoresis and 
purified with the QIAquick Gel Extraction Kit (QIAGEN) according to the manufacturer’s 
protocols. PCR products were sequenced by Genewiz, Inc. Nucleotide sequences were 
compared with reference strain sequences to determine genotypes (21).
TCH Stool Microbiology Studies
Stool microbiology studies for other enteric pathogens were performed at the treating 
physician’s discretion. Clostridium difficile was detected by a real-time PCR assay 
amplifying toxin A (tcdA) and B (tcdB) genes (22). A membrane-based immunogold assay 
was used as the initial rotavirus assay with secondary electron microscopy (EM) analysis on 
rotavirus-negative samples from January 1st to May 31st of each year. EM was used alone 
for rotavirus and adenovirus identification throughout the remaining year. Adenovirus was 
also detected by quantitative real-time PCR. Cytomegalovirus (CMV) screening was 
performed by quantitative real-time PCR of plasma specimens and qualitative real-time PCR 
of fecal samples (Viracor-IBT Laboratories). Immunofluorescence assay for CMV 
antigenemia in peripheral blood leukocytes was available upon request. Stool samples were 
screened for enteric bacterial pathogens, including Salmonella sp., Shigella sp., Yersinia sp., 
Campylobacter jejuni, Aeromonas sp., and Plesiomonas sp. by selective media (23). Shiga-
toxin producing Escherichia coli (STEC) were detected by inoculating the stool in 
MacConkey broth (Remel), followed by stx1 and stx2 toxin-specific enzyme immunoassay 
(Premier EHEC, Meridian Bioscience, Inc.). An EIA was performed for Cryptosporidium 
sp. and Giardia sp. detection (ImmunoCard STAT, Meridian Bioscience, Inc.). Stool 
examination for ova and parasites was performed by microscopy (ARUP Laboratories). 
Beginning in January 2013, a multiplex nucleic acid amplification assay using Luminex® 
xTag® technology became available for detecting Campylobacter sp., C.difficile toxins A 
and B, Cryptosporidium sp., E. coli O157, Enterotoxigenic E. coli (LT/ST), STEC stx1/stx2, 
Giardia lamblia, GI and GII NoVs, rotavirus A, Salmonella sp., and Shigella sp. (xTAG® 
Gastrointestinal Pathogen Panel, Viracor-IBT Laboratories, Inc.).
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Statistical analysis
Clinical characteristics and outcomes of subjects experiencing first NoV diarrhea episodes 
were compared to non-NoV diarrhea subjects, who were systematically selected as the first 
NoV-negative subject with a matching organ transplant type enrolled after a NoV diarrhea 
subject was identified. Subjects receiving any tube feeding after enrollment, including those 
receiving chronic enteral nutrition, were included in the epidemiologic surveillance for NoV 
diarrhea in transplant patients, but were excluded from the matched case-control and viral 
load analyses because tube feeding can potentially cause diarrhea. NoV and non-NoV 
diarrhea patients identified with alternative enteropathogens were included in the matched 
case-control comparison. NoV viral load was correlated with continuous variable host 
characteristics and outcomes by Spearman correlation coefficient. Significant proportional 
differences were evaluated with chi-square analysis for categorical variables. Continuous 
variables were compared by Wilcoxon ranksum test. Statistical analyses were conducted 
using SAS (version 9.1) software.
Results
One hundred sixteen transplant recipients, including 61 SOT and 55 HSCT patients, were 
enrolled from December 1, 2012 to September 1, 2013. The mean age (± SD) of the 
transplant recipients was 9 ± 6.8 years, and 55% of subjects were male. Forty-percent of 
subjects were of Hispanic ethnicity, 78% of Caucasian race. The average duration from date 
of transplantation to enrollment (± SD) was 433 ± 879.4 days; 126 ± 302.2 days for HSCT 
patients and 734.3 ± 1,127.1 days for SOT patients (p<0.01).
Noroviruses were detected in 25 (22%) of the transplant patients with diarrhea (n=116), 
including 9 SOT and 16 HSCT patients (Tables S1 and S2). NoVs were identified more 
frequently than any other enteric pathogen, even when the number of tests performed for 
each enteropathogen was taken into consideration (Table 2). Other diarrheal pathogens 
included adenovirus (12%), C. difficile (7%), rotavirus (3%), Salmonella sp. (2%), and 
Cryptosporidium sp. (1%). Co-pathogens were identified among five NoV patients, 
including rotavirus (n=2), C. difficile (n=1), adenovirus (n=1), and both C. difficile and 
adenovirus (n=1). Alternative enteropathogens were detected in 22 NoV-negative patients. 
Three of 18 (17%) NoV patients screened positive for cytomegalovirus (CMV) viremia, but 
none had confirmation of gastrointestinal invasive disease by histopathology. The majority 
(76%) of NoV diarrhea cases were community-associated, while 24% were healthcare-
associated.
All NoV strains were identified as GII NoVs. NoV genotypes were successfully determined 
for 19 patients and included GII.4 (n=12), GII.3 (n=4), GII.6 (n=3), GII.7 (n=1), and GII.2 
(n=1) strains (Figure). NoV genotypes, different from the original strain and confirmed by 
repeated sequencing, were detected in two transplant patients during their diarrheal episode. 
One GII.6 NoV patient was later infected with a GII.3 strain. The second patient was 
positive for a GII.4 NoV strain twice over two months, followed by a GII.3 strain ~four 
months later, and then the original GII.4 NoV strain one month afterwards. Based on 
sequence analysis, GII.4 co-infection of the GII.3 strain in this patient cannot be excluded, 
but further confirmation by cloning and NoV capsid sequencing is necessary (24).
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Fifty percent of transplant recipients with NoV diarrhea experienced persistent diarrhea 
lasting ≥14 days, and the median duration of NoV diarrhea was 12.5 days (range 1 – 324 
days) (Table 3). The median maximum number of stools passed in a 24-hour period was 9 
stools (range 3 – 16 stools). Approximately 30% of NoV diarrhea patients developed 
recurrent diarrhea within one month of NoV diarrhea resolution. Fifty-five percent of NoV 
patients were hospitalized for their diarrhea; 27% of these patients required intensive care 
unit (ICU) admission during their diarrhea. Precipitating events requiring ICU admission 
among NoV diarrhea patients included severe dehydration and hypovolemia from 
uncontrolled diarrhea (n=2), respiratory distress (n=2), septic shock (n=1), and cardiac 
arrhythmia (n=1). Three HSCT patients expired ≤6 months of NoV diarrhea onset. Two 
deaths were secondary to sepsis; one death was related to pulmonary hemorrhage. One 
patient suffered chronic diarrhea for >300 days, which continued until his death. Diarrhea 
persistence contributed to his steady physical decline and required prolonged parenteral 
nutrition, which ultimately led to fatal septic complications. NoV shedding was detected in 
this patient’s stools for 238 days, after which no further stools were available for testing. 
The patient died approximately 3 months after the last NoV-positive stool. Gastrointestinal 
graft-versus-host disease (GVHD) and tube feeding may have also contributed to his chronic 
diarrhea. Bloody stools were noted in 1 HSCT and 2 SOT patients and pneumatosis 
intestinalis in 1 HSCT patient; NoVs were the only enteropathogen identified in these 
patients. One additional HSCT patient developed bloody diarrhea, but was also positive for 
adenovirus.
To compare host characteristics and diarrhea severity between NoV diarrhea and non-NoV 
diarrhea transplant recipients, we performed a matched case-control analysis of NoV 
diarrhea subjects (n=22) and non-NoV diarrhea subjects (n=22), after excluding 3 NoV-
positive subjects (2 HSCT and 1 SOT patients) who received tube feeding. NoV diarrhea 
patients were significantly more frequently admitted to the ICU during their diarrhea (27% 
vs. 0%, p = 0.02), experienced a greater rise in serum creatinine (median 0.3 vs. 0.2 mg/dL, 
p = 0.01), and lost more weight (median 1.6 vs. 0.6 kg, p < 0.01) than non-NoV diarrhea 
patients. NoV diarrhea patients were also more frequently admitted to the hospital for 
diarrhea, experienced greater diarrhea persistence, and passed more stools within a 24-hour 
period than non-NoV diarrhea patients; however, these differences were not statistically 
significant.
Three (14%; 3 HSCT) patients developed NoV diarrhea prior to transplantation (1–3 days), 
2 (9%; 2 HSCT) <1 month after transplantation, 6 (27%; 5 HSCT, 1 SOT) 1–6 months after 
transplantation, and 11 (50%; 4 HSCT, 7 SOT) >6 months after transplantation. Onset of 
non-NoV diarrhea in relation to transplantation, including more frequent diarrhea in the late 
post-transplantation period for SOT than HSCT patients, was similarly distributed.
NoV diarrhea was more prevalent among HSCT patients (30%) than in SOT patients (13%, 
p = 0.03). NoV HSCT patients were significantly younger (mean ± SD, 8.3 ± 5.7 vs. 14.2 ± 
5.5 years, p = 0.02) and more likely to experience diarrhea recurrence (46% vs. 0%, p <0.05) 
than NoV SOT patients. Graft-versus-host disease (GVHD) was present in 8 HSCT patients 
with NoV diarrhea, including 3 recipients with gastrointestinal GVHD. Two patients were 
diagnosed endoscopically with gut GVHD during their diarrheal episode and received 
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increased immunosuppression; however, their diarrhea was refractory and persisted for 98 – 
301 days. One patient with a past history of gastrointestinal GVHD developed diarrhea, 
which was attributed to NoV gastroenteritis. CMV viremia (range 200 – 5,200 copies/mL) 
was detected in 3 NoV HSCT patients. Two of these patients received either ganciclovir or 
valganciclovir for viremia; however, CMV infection was not deemed as contributing to the 
diarrhea by the treating physicians. No significant differences in NoV diarrhea severity, 
regarding duration, number of diarrheal stools, associated complications including hospital 
or ICU admission, or laboratory abnormalities between the two transplant groups were 
observed (data not shown).
The mean NoV viral load was 6.3 × 108 genomic copies per gram of stool among NoV 
diarrhea patients. NoV fecal load was similar between HSCT and SOT patients (mean 7.4 × 
108 vs. 4.3 × 108 genomic copies per gram of stool, p = 0.68). Fifteen of the twenty-five 
NoV diarrhea subjects (60%) provided ≥1 additional stool samples collected ≥14 days apart. 
Nine (60%) of these NoV diarrhea patients were persistently positive, with median NoV 
shedding duration of 31 days (range 14 – 238 days). Three subjects continued to shed NoVs 
asymptomatically after diarrhea resolution, ranging from 10 – 91 days. Greater NoV load 
was significantly correlated with increased maximal number of stools in a 24-hour period (rs 
= 0.50, p = 0.03). No correlation was observed between NoV shedding and other measures 
of diarrhea severity (duration), complications (fever, renal insufficiency, weight loss, 
hospital or ICU requirement), or host absolute lymphocyte count at diarrhea onset (data not 
shown).
Discussion
SOT and HSCT recipients are at high risk for developing infections because of their 
significant immunosuppression related to their underlying disease, immunosuppressive 
therapy for organ engraftment and prevention of organ rejection, delayed immune recovery 
following transplantation, and complications such as graft-versus-host disease (25). Humoral 
and cell-mediated immunosuppression likely render SOT and HSCT recipients susceptible 
to NoV infection and severe disease and impair their ability to clear NoV infection.
Case reports and small, retrospective studies have described severe, prolonged NoV disease 
among immunocompromised hosts complicated by fever, recurrent hospitalizations for 
dehydration (26), chronic diarrhea persisting months to years (12), acute renal failure 
requiring hemodialysis (13, 14), weight loss, malnutrition requiring supplemental enteral or 
parenteral nutrition (13), enteritis (15), pneumatosis intestinalis (27), peritonitis (15), 
impaired mucosal barrier function with secondary bacteremia (15, 28), and death (12, 15). 
However, these studies were primarily anecdotal and included relatively few transplant 
patients. We conducted a large, prospectively enrolled surveillance study in an attempt to 
better define the epidemiologic and clinical significance of NoV diarrhea among pediatric 
transplant recipients.
Overall NoV prevalence was 22% among pediatric transplant recipients with diarrhea. NoVs 
were the most common enteric pathogen identified, almost as common as all other 
enteropathogens collectively. The majority of NoV diarrhea cases were associated with the 
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community, but approximately 25% of patients were diagnosed with NoV infection in the 
healthcare setting. NoV diarrhea was often severe in these children, lasting on average >1 
month, requiring frequent hospitalization for uncontrolled diarrhea, and was associated with 
dehydration and malnutrition complications and ICU admission. Four NoV diarrhea 
patients, including two patients excluded from the matched case-control analysis for receipt 
of tube feeding, required ICU admission for complications from severe diarrhea. One patient 
developed pneumatosis intestinalis. Three NoV patients died within 6 months of NoV 
diagnosis, including one death related to persistent diarrhea.
Establishing the etiology of diarrhea in immunocompromised hosts is challenging, with a 
myriad of potential causes including medications such as immunosuppressants and 
antibiotics, infection, chronic gastrointestinal disorders, immune phenomenon such as 
allograft rejection and GVHD, post-transplantation lymphoproliferative disease in SOT 
patients, and mucositis secondary to conditioning regimens in HSCT recipients (29–31). In 
addition, asymptomatic NoV infection has been described in up to one-third of healthy 
persons exposed to NoVs (32). Asymptomatic NoV prevalence among 
immunocompromised individuals is unknown. In our study, NoV diarrhea transplant 
patients required significantly more frequent ICU admission and experienced greater renal 
insufficiency and weight loss than non-NoV diarrhea patients. Worse renal insufficiency in 
NoV patients likely resulted from significant diarrhea-related dehydration. These adverse 
clinical outcomes associated with NoV diarrhea support the pathogenic role of NoV 
infection in these transplant recipients.
Distinguishing NoV disease from asymptomatic infection based on higher NoV loads has 
been proposed (33). However, the majority of studies evaluating the association between 
NoV fecal concentrations and clinical manifestations comprised immunocompetent hosts 
and reported conflicting results (17, 34, 35). Higher NoV fecal loads were associated with 
increased diarrheal stools in a 24-hour period in our transplant cohort, but did not correlate 
with other diarrhea severity markers. NoV shedding persisted a median of 31 days and up to 
238 days. Future systematic collection and testing of stools from NoV-positive patients 
needs to be performed to more precisely assess NoV persistence in transplant patients. 
Chronic NoV shedding may have contributed to nosocomial acquisition of NoV infection, 
leading to the significant proportion of healthcare-associated NoV cases. However, 
additional epidemiologic and NoV sequencing studies are needed to confirm nosocomial 
transmission in our transplant patient cohort. Optimal infection control measures for 
persistent immunocompromised NoV shedders need to be established. These chronic NoV-
infected hosts may also represent a reservoir for the emergence of new epidemic strains after 
accelerated NoV genomic evolution (36).
SOT patients usually experience maximal immunosuppression 1 – 6 months after 
transplantation. Allogeneic HSCT recipients may undergo even more profound 
immunosuppression with myeloablative regimens, which eradicate the recipient’s 
lymphohematopoietic system in preparation for donor stem cell transfer. In our study, HSCT 
patients presented with diarrhea earlier after transplantation than SOT patients, which likely 
reflects this severe immunosuppression prior to stem cell engraftment. In our matched case-
control cohort, HSCT recipients also had significantly lower median white blood cell (2.6 
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vs. 9.1 cells/µL, p < 0.01) and median absolute lymphocyte counts (279 vs. 1,035 cells/µL, p 
< 0.01) than SOT patients. In addition, 8 HSCT patients had GVHD. Greater 
immunosuppression among HSCT patients likely led to significantly higher NoV diarrhea 
prevalence and recurrence in HSCT patients compared to SOT subjects.
Study limitations include the passive enrollment and surveillance of subjects. Only subjects 
who submitted stool samples to the TCH microbiology laboratory and experienced diarrhea 
were enrolled. Another study limitation was the collection of clinical information from 
medical records. Stool frequency and form were well-documented in hospital records for 
patients admitted to the hospital, but more variable for outpatients. Although this study only 
enrolled transplant patients with diarrhea, a minority of patients (n=9) began having diarrhea 
symptoms prior to their transplantation. These patients were included, as previously 
published case reports have described significant NoV morbidity in HSCT patients who 
acquired NoV infection prior to their HSCT (9, 37). An additional study limitation was the 
inclusion of NoV-positive and – negative subjects identified with other diarrheal pathogens 
in our matched case-control comparison of NoV-diarrhea and non-NoV diarrhea subjects. 
Subjects with co-pathogens were not excluded to avoid potentially underpowering our 
analysis, given the relatively small number of subjects. While these other diarrheal 
pathogens may have contributed to clinical outcomes attributed to NoVs, non-NoV diarrhea 
subjects with co-pathogens were also included. Finally, we cannot exclude that transplant 
patients with NoV infection may have developed diarrhea due to other causes. However, the 
worse clinical outcomes observed with NoV diarrhea support the pathogenic role of 
noroviruses in these immunocompromised patients.
Noroviruses are an important cause of diarrhea and are associated with significant 
complications in immunocompromised pediatric transplant recipients. However, studies are 
urgently needed to further define NoV pathogenesis in transplant recipients. Establishing 
NoVs as the causative diarrheal agent in a timely manner is critical to improving clinical 
management and limiting unwarranted adverse effects from antibiotics for possible bacterial 
diarrhea; invasive, endoscopic procedures to diagnose GVHD; and inappropriate escalation 
of immunosuppression for presumed gastrointestinal GVHD rather than reduction to control 
NoV infection. Immunocompromised transplant patients represent an important population 
susceptible to norovirus diarrhea, who may benefit from future novel therapeutic and 
preventative strategies such as immunoglobulin therapy (38), including monoclonal 
antibodies (39), or norovirus antivirals or vaccines (40).
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Abbreviations
NoV norovirus
SOT solid organ transplantation
HSCT hematopoietic stem cell transplantation
GI genogroup I
GII genogroup II
ICU intensive care unit
TCH Texas Children’s Hospital
RT-PCR reverse transcription polymerase chain reaction
EM electron microscopy
STEC Shiga-toxin producing Escherichia coli
CMV cytomegalovirus
GVHD graft-versus-host disease
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Figure. 
Norovirus Genotypes Identified
Note. Phylogenetic analysis of genogroup II (GII) norovirus (NoV) strains identified from 
pediatric transplant recipients based on partial nucleotide sequences of the NoV capsid gene. 
The dendogram was constructed by the maximum likelihood method using the software 
MEGA 6.0. A Kimura 2-parameter model was used for nucleotide substitution; substitution 
rates were assumed to be gamma distributed. Study samples are listed by subject number, 
sample number (e.g., 6.1); location (TCH, Texas Children’s Hospital), month (for patients 
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with NoV detection on more than one occasion), and year of collection. Percentage 
bootstrap values are shown at the branch nodes. The scale indicates nucleotide substitutions 
per site. Subjects 6 and 10 were positive for different GII NoV genotypes during their 
diarrheal episode.
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Table 1
Primer and probe sequences for conventional (NoV genotyping) and real-time RT-PCR (NoV detection)
Purpose Primer/probe Sequence (5′–3′) Amplicon
size (bp)
GI detection
COG IF CGYTGGATGCGITTYCATGA
85COG IR CTTAGACGCCATCATCATTYAC
Ring 1C FAM - AGATYGCGITCICCTGTCCA - BHQ
GII detection
COG 2F CARGARBCNATGTTYAGRTGGATGAG
98COG 2R TCGACGCCATCTTCATTCACA
Ring 2 JOE - TGGGAGGGCGATCGCAATCT - BHQ
GI genotyping
G1SKF CTGCCCGAATTYGTAAATGA
330
G1SKR CCAACCCARCCATTRTACA
GII genotyping
G2SKF CNTGGGAGGGCGATCGCAA
344
G2SKR CCRCCNGCATRHCCRTTRTACAT
Note: FAM, 6-carboxyfluorescein; BHQ, Black Hole Quencher; JOE, 2,7 dimethoxy-4,5-dichloro-6-carboxyfluorescein.
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Table 2
Enteric Pathogen Prevalence in Transplant Recipients (n=116)
Enteric Pathogen Prevalence
(% Total Subjects)
No. Tests Performed
(% Positive)
Norovirus 25 (22) 116 (22)
Adenovirus 14 (12) 71 (20)
Clostridium difficile 8 (7) 92 (9)
Rotavirus 3 (3) 60 (5)
Salmonella sp. 2 (2) 96 (2)
Cryptosporidium sp. 1 (1) 58 (2)
Giardia sp. 0 58 (0)
Shigella sp. 0 96 (0)
Campylobacter sp. 0 96 (0)
STEC* 0 96 (0)
Yersinia sp. 0 96 (0)
Note.
Abbreviation: STEC, Shiga-toxin producing Escherichia coli
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Table 3
Characteristics of Transplant Recipients with Norovirus (NoV) Diarrhea and non-NoV Diarrhea*
NoV Diarrhea
(n=22)
non-NoV Diarrhea
(n=22)
P-value
Age, mean years ± SD 10.4 ± 6.2 9.3 ± 7.2 0.49
Female patient (%) 11 (50) 7 (32) 0.22
Duration from transplantation to diarrhea onset (days)
  Median 136.5 93 0.77
  Range −3 to 1962 −5 to 4079
Hospital admission for diarrhea (%) 12 (55) 8 (36) 0.23
Intensive care unit admission during diarrhea episode (%) 6 (27) 0 0.02
Median white blood cell count (cells/uL) (range)‡ 4.3 (0–14.1) 4.1 (0–11.8) 0.72
Median absolute lymphocyte count (cells/uL) (range)‡ 777 (0–6453) 392 (0–2068) 0.59
Presence of fever at diarrhea onset (%) 7 (32) 8 (36) 0.75
Median duration of diarrhea (range) 12.5 (1–324) 7 (1–34) 0.16
Persistent diarrhea** (%) 11 (50) 8 (36) 0.36
Recurrence of diarrhea† 6 (29) 7 (33) 0.74
Median maximum no. stool in 24 hours (range) 9 (3–16) 8 (3–14) 0.16
Median rise in serum creatinine (mg/dL) during diarrhea (range) 0.3 (0–1.4) 0.2 (0–0.9) 0.01
Median weight loss (kg) during diarrhea (range) 1.6 (0–7) 0.6 (0–3.8) <0.01
Required total parenteral nutrition during diarrhea (%) 12 (55) 8 (37) 0.23
Death during diarrhea episode (%) 1 (5) 0 1.00
Death within 6 months of diarrhea onset (%) 2 (9) 1 (5) 1.00
Note:
*
Transplant patients receiving tube feeding were excluded, including 3 NoV diarrhea subjects, one of whom expired ≤6 months of diarrhea onset. 
Five NoV diarrhea patients were co-infected with C. difficile (n=2), rotavirus (n=2), or adenovirus (n=2). Four non-NoV diarrhea patients were 
identified with C. difficile (n=2) or adenovirus (n=2).
‡Within 24 hours of diarrhea onset.
**
Persistent diarrhea was defined as diarrhea duration ≥14 days.
†
Recurrence of diarrhea >1 week but ≤4 weeks of diarrhea resolution. Data for diarrhea recurrence was not available for 1 NoV and 1 non-NoV 
patient.
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